Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
AstraZeneca
Moodys
Express Scripts

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ponesimod

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Ponesimod?

Ponesimod is an investigational drug.

There have been 8 clinical trials for Ponesimod. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2015.

The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Actelion, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].

There are two US patents protecting this investigational drug and nineteen international patents.

Recent Clinical Trials for Ponesimod
TitleSponsorPhase
A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady StateJanssen Pharmaceutica N.V., BelgiumPhase 1
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisActelionPhase 3
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)ActelionPhase 3

See all Ponesimod clinical trials

Clinical Trial Summary for Ponesimod

Top disease conditions for Ponesimod
Top clinical trial sponsors for Ponesimod

See all Ponesimod clinical trials

US Patents for Ponesimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ponesimod   Start Trial Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimi- no)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process ACTELION PHARMACEUTICALS LTD. (Allschwil, CH)   Start Trial
Ponesimod   Start Trial Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same KYOTO UNIVERSITY (Kyoto-shi, JP) ASTELLAS PHARMA INC. (Chuo-ku, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ponesimod

Drugname Country Document Number Estimated Expiration Related US Patent
Ponesimod Canada 2895172 2032-08-17   Start Trial
Ponesimod China 104540800 2032-08-17   Start Trial
Ponesimod European Patent Office 2885266 2032-08-17   Start Trial
Ponesimod Israel 237198 2032-08-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Mallinckrodt
Boehringer Ingelheim
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.